News Releases
Dec 12, 2025
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced
Nov 17, 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), and Halozyme
Oct 24, 2025
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Oct. 24, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Oct 14, 2025
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Oct. 14, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Oct 13, 2025
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT , The Netherlands and CAMBRIDGE, Mass., Oct.
Sep 29, 2025
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction
Aug 28, 2025
Merus to Present at the 2025 Wells Fargo Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), today announced that Bill
Aug 06, 2025
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), today announced that Bill
Aug 05, 2025
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 6 3% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating plan, existing cash, cash equivalents, including
Aug 04, 2025
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and
Jun 04, 2025
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and
Jun 03, 2025
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and
May 27, 2025
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg ,
May 22, 2025
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
May 15, 2025
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics
May 08, 2025
Merus to Present at BofA Securities 2025 Health Care Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief Executive Officer
May 07, 2025
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO ® Annual Meeting - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into
Apr 23, 2025
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT , The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) --
Apr 01, 2025
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), today announced that Bill
Feb 27, 2025
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2
Feb 25, 2025
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), today announced
Feb 18, 2025
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® ,
Feb 13, 2025
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg , M.D., President, Chief
Feb 05, 2025
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that the New
Jan 12, 2025
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs),